+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 145 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the use of 3D-printed custom applicators for intracavitary high-dose-rate HDR brachytherapy in patients with gynaecological cancers, including endometrial, vaginal, vulva, and recurrent gynaecological cancers. This Phase IIa non-randomised pilot trial aims to assess the feasibility of treating patients using these patient-specific devices, which could offer a more precise and efficient alternative to traditional cylinder-type applicators or custom wax moulds. The study is sponsored by Royal North Shore Hospital and addresses current challenges in applicator design and construction. Participants will receive treatment using 3D-printed custom applicators designed to match optimal planning specifications for HDR brachytherapy. This innovative approach may reduce the time and labor involved in applicator preparation compared to standard wax moulds, while providing a robust and tailored device for therapy. The study focuses on intracavitary brachytherapy procedures for eligible female patients with certain stages of gynaecological cancer. During the study, patients will be closely monitored for treatment success, radiation therapy toxicities, and quality of treatment plans. Researchers will also evaluate the feasibility of MR-only and CT-only planning procedures, optimize applicator design, and assess resource use and costs. Patient experience and acceptability will be measured via questionnaires over a five-year follow-up. Safety and effectiveness outcomes will be carefully tracked to understand the potential benefits and challenges of this new technology.

Age: 18Years +FEMALEPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and pharmacokinetics of SHR-4685 in adults with advanced solid tumors. This phase I study aims to determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of SHR-4685, helping to understand how the drug behaves in the body and its potential side effects. Participants will receive SHR-4685 in varying doses as part of a single treatment group. The study monitors participants for up to 24 months to assess adverse events, serious adverse events, and drug concentration levels in plasma. The treatment period includes regular assessments at predefined intervals to gather detailed pharmacokinetic data and observe tumor response measures. During the study, participants will undergo evaluations including tumor measurements based on RECIST 1.1 criteria, laboratory tests to monitor organ function and presence of antibodies against SHR-4685, and safety assessments to track side effects. Researchers will measure outcomes such as objective response rate, disease control rate, duration of response, and progression-free survival. Safety monitoring continues for 30 days after the last dose, and the total participation can last up to two years.

Age: 18Years - 75YearsAll GendersPhase 1
6 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and how the body processes HRS-3802 when used alone in patients with advanced malignant solid tumors. This phase I clinical study aims to better understand these factors in patients whose tumors have either not responded to standard treatments or for whom no effective standard treatments exist. The study is sponsored by Shandong Suncadia Medicine Co., Ltd. Participants will receive HRS-3802 as a single treatment. The study is open-label, meaning both participants and researchers know the treatment being given. The research includes monitoring for side effects and determining the maximum tolerated dose and recommended dose for future studies. Treatment effects will be assessed over several months, with follow-up evaluations up to two years for progression and response. During the study, participants will be monitored regularly for adverse events, dose-related toxicities, and tumor response using RECIST 1.1 criteria. Safety assessments will occur every four weeks, especially during the first 28 days of treatment. Researchers will also evaluate outcomes such as objective response rate, duration of response, and progression-free survival. Participants are expected to survive at least 12 weeks and will be followed for up to two years to assess treatment impact and safety.

Age: 18Years +All GendersPhase 1
6 locations
E

Actively Recruiting

Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.

Age: 18Years +All GendersPhase 3
124 locations
P

Actively Recruiting

This trial is designed for adults diagnosed with metastatic pancreatic ductal adenocarcinoma PDAC who have not yet received systemic treatment for their advanced cancer and have a good performance status. The study evaluates pumitamig, an investigational drug, in combination with chemotherapy to assess its safety and effectiveness. This phase II trial plans to explore different chemotherapy regimens combined with pumitamig to understand their impact on the disease.

Age: 18Years +All GendersPhase 2
24 locations
T

Actively Recruiting

Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.

Age: 18Years +All GendersPhase 1Phase 2
86 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
P

Actively Recruiting

Researchers are conducting a Phase 1 dose-escalation and dose-confirmation study to assess the safety and anti-cancer activity of UB-VV111 in patients with relapsed or refractory large B-cell lymphoma LBCL and chronic lymphocytic leukemia CLL. This study focuses on patients who have previously undergone treatment and aims to evaluate the investigational gene therapy UB-VV111, which produces CD19 CAR T cells inside the body. Participants will receive either a single dose of UB-VV111 alone or a single dose of UB-VV111 followed by treatment with rapamycin, an FDA-approved drug. The study uses a sequential design to monitor outcomes over time and includes two experimental groups one with UB-VV111 only and another combining UB-VV111 with rapamycin. During the study, participants will be monitored for adverse events for up to 2 years after receiving UB-VV111. Researchers will also evaluate overall response rates to the treatment. The study involves multiple assessments of disease status and safety, including measuring disease according to standard criteria and tracking organ function and performance status. The total participation duration extends up to two years for safety and efficacy follow-up.

Age: 18Years +All GendersPhase 1
9 locations
P

Actively Recruiting

Researchers are evaluating HLX48, an EGFRc-MET bispecific antibody-drug conjugate, in patients with advanced or metastatic solid tumors. This open-label phase I clinical trial aims to assess the safety, tolerability, and pharmacokinetic profile of HLX48 given at increasing doses. The trial uses a 33 dose escalation design to carefully study the effects and side effects of HLX48 in this patient population. Participants will receive HLX48 via intravenous infusion at one of six preset dose levels. The dose-limiting toxicity DLT observation period lasts for 3 weeks after the first dose, during which the Safety Review Committee reviews safety data to decide on dose escalation or cohort expansion. New dose groups may be added based on safety, tolerability, pharmacokinetics, immunogenicity, and efficacy data. Those who withdraw early for reasons unrelated to toxicity may be replaced. Throughout the study, participants will undergo evaluations including tumor measurements by RECIST v1.1, ECOG performance status assessments, and laboratory tests to confirm organ function. Safety monitoring includes dose-limiting toxicity and maximum tolerated dose assessments within the first cycle of treatment. Secondary outcomes such as response rates, survival, and antibody development will be tracked for up to 24 months. Participants are followed closely during and after treatment to collect comprehensive data on HLX48s effects.

Age: 18Years - 75YearsAll GendersPhase 1
7 locations

1-10 of 145

1